Amgen’s $125 Per Share Offer For Onyx Reflects Kyprolis Uncertainty

Amgen will acquire the cancer company Onyx for $125 per share, or $10.4 billion. That's higher than the $120 per share Amgen originally offered, but less than some investors and analysts thought obtainable.